- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Report: Novartis continues efforts to sell off some ophthalmology assets
The company has said it hopes to make the deals to be able to focus on its core areas.
Despite moving forward and reaching out to potential suiters, Novartis could still decide against the sale. (Adobe Stock image)
Novartis is set to kick off the sale of some of its ophthalmology portfolio assets as it plans to focus more on its core areas, according to a report today by Bloomberg News.
According to reports, the assets on the block include dry eye therapy Xiidra, which had revenues of $487 million in 2022. Bloomberg added the company has engaged an adviser to check interest in the so-called front-of-eye therapies, the report added.
Novartis acquired Xiidra from Takeda Pharmaceutical in 2019 for $3.4 billion in upfront cash plus up to an additional $1.9 billion in milestones.
Moreover, the report cited sources that noted the assets for sale do not include wet age-related macular degeneration therapy Lucentis, which generated about $1.87 billion in revenue last year.
Despite moving forward and reaching out to potential suiters, Novartis could still decide against the sale.
In August, Novartis first announced plans to spin off the Sandoz generics unit as it directed its focus on the development of patented prescription medications.
Last month, Gilbert Ghostine was named chairman-designate of Sandoz.
He will become the chairman of the new board at Sandoz, which is to be formed after its spin-off from Novartis in the second half of 2023, subject to final Novartis Board of Directors and shareholder approvals.
In 2019, Novartis spun off the Alcon eye care business, and in 2021 sold approximately a third of its voting share in Roche.
The company continues to see successes in its ophthalmology pipeline.
In June, Novartis announced that the FDA had approved brolucizumab-dbll 6 mg (BEOVU) for the treatment of diabetic macular edema (DME). The drug had been approved by the European Commission in April.
The company also announced June 20 it purchased Kedalion Therapeutics and its AcuStream technology.
Kedalion Therapeutics is a clinical-stage, venture-funded ophthalmic drug company based in California. The company announced the completion of its Series B funding—led by Novartis—in November 2021.
Novartis did not respond to Bloomberg News for its report.
